Myriad Genetics, Inc. (MYGN) Tops Q1 EPS by 1c, Reaffirms FY12 Guidance

Article Stock Quotes (1) Comments (0)

Myriad Genetics, Inc. (NASDAQ: MYGN) reported Q1 EPS of $0.29, $0.01 better than the analyst estimate of $0.28. Revenue for the quarter came in at $110.5 million versus the consensus estimate of $106.49 million.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: Jabil Circuit, Inc. (JBL) Tops Q3 EPS by 2c; Issues Light Q4 Outlook; Will Realign Global Ops
• DaVita Labs and Myriad RBM Announce Biomarker Research Collaboration
• Steelcase Inc. (SCS) Misses Q1 EPS by 3c, Q2 Guidance Light

Create E-mail Alert Related Categories

Earnings

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?